EUVIMEDEUVIMED entdecken
Open Access

Darolutamide With Concomitant Lipid-Modifying Agents in Nonmetastatic Castration-Resistant Prostate Cancer

Murilo A Luz, Alberto Briganti, Declan G Murphy, Christopher M Pieczonka, Hiroyoshi Suzuki, Evan Y Yu, Xavier Artignan, Geoffrey T Gotto, Joelle P Hamilton, Ryan J Malone, Patrick Adorjan, Mercedeh Ghadessi und 2 weitere

JAMA Network Open · 19.08.2026 · 9 (8) · e2629936

DOI: 10.1001/jamanetworkopen.2026.29936 ↗

Kurz gefasst

Fachartikel in der Zeitschrift JAMA Network Open, online erschienen am 19.08.2026. Verfasst von Murilo A Luz und 13 weiteren Autor:innen. Beteiligte Einrichtung: Hospital Erasto Gaertner, Curitiba, Brazil. Die Arbeit nennt 7 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

This nonrandomized clinical trial assesses the safety and efficacy of darolutamide, with or without concomitant lipid-modifying agents (LMAs), in treating nonmetastatic castration-resistant prostate cancer.

Autor:innen und Institutionen

  • Hospital Erasto Gaertner, Curitiba, Brazil.
  • Now with Icahn School of Medicine at Mount Sinai, New York, New York.
  • Urological Research Institute, IRCCS Ospedale San Raffaele and Università Vita-Salute San Raffaele, Milan, Italy.
  • University of Melbourne and Peter MacCallum Cancer Centre, Melbourne, Australia.
  • Associated Medical Professionals of NY, US Urology Partners, Syracuse, New York.
  • Toho University Sakura Medical Center, Chiba, Japan.

Zitieren

APA

Luz, M. A., Briganti, A., Murphy, D. G., Pieczonka, C. M., Suzuki, H., Yu, E. Y., Artignan, X., Gotto, G. T., Hamilton, J. P., Malone, R. J., Adorjan, P., Ghadessi, M., Verholen, F., & Armstrong, A. J. (2026). Darolutamide With Concomitant Lipid-Modifying Agents in Nonmetastatic Castration-Resistant Prostate Cancer. JAMA Network Open, 9(8), e2629936. https://doi.org/10.1001/jamanetworkopen.2026.29936

Vancouver

Luz MA, Briganti A, Murphy DG, Pieczonka CM, Suzuki H, Yu EY, et al. Darolutamide With Concomitant Lipid-Modifying Agents in Nonmetastatic Castration-Resistant Prostate Cancer. JAMA Network Open. 2026;9(8):e2629936. doi:10.1001/jamanetworkopen.2026.29936

BibTeX
@article{Luz2026,
  author = {Luz, Murilo A and Briganti, Alberto and Murphy, Declan G and Pieczonka, Christopher M and Suzuki, Hiroyoshi and Yu, Evan Y and Artignan, Xavier and Gotto, Geoffrey T and Hamilton, Joelle P and Malone, Ryan J and Adorjan, Patrick and Ghadessi, Mercedeh and Verholen, Frank and Armstrong, Andrew J},
  title = {Darolutamide With Concomitant Lipid-Modifying Agents in Nonmetastatic Castration-Resistant Prostate Cancer},
  journal = {JAMA Network Open},
  year = {2026},
  volume = {9},
  number = {8},
  pages = {e2629936},
  doi = {10.1001/jamanetworkopen.2026.29936}
}
Kostenlos starten →